Orionis Biosciences

Orionis' business model revolves around the development and clinical testing of their drug candidates. They are currently in the clinical trial phase for their drug ORB-011, which is being tested as a single agent treatment for patients with advanced solid tumors. The company generates revenue through the successful development, approval, and subsequent sale of their drugs.

The company's pipeline includes targeted cytokine immunotherapies, which are treatments that use the body's immune system to fight diseases, and molecular glue drug modalities. The latter are small molecules that act in a unique way to target and degrade disease-causing proteins, a method that could potentially treat diseases that have been historically difficult to target with drugs.

Orionis also develops A-Kines, a new type of drug that uses common molecular building blocks to create biologics with superior cell target selectivity. This means these drugs can more accurately target and treat specific cells in the body, potentially improving their effectiveness and reducing side effects.

The company is headquartered in Boston, MA, and Ghent, Belgium, and has recently added Tony Fadell, inventor of the iPod and co-inventor of the iPhone, to its board of directors.